Praxis Precision Medicines, Inc. PRAX Long-term marketable securities
Long-term marketable securities at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s long-term marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s long-term marketable securities?
- Praxis Precision Medicines, Inc. (PRAX) reported long-term marketable securities of $911.47M in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s long-term marketable securities changed year-over-year?
- Praxis Precision Medicines, Inc.'s long-term marketable securities increased by 532.8% year-over-year, from $144.03M to $911.47M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s long-term marketable securities?
- Over 3 years (2021 to 2025), Praxis Precision Medicines, Inc.'s long-term marketable securities has grown at a 162.3% compound annual growth rate (CAGR), from $31.53M to $568.76M.